Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Efforts to advance chronic disease prevention through enhanced education, awareness and support — kicking off during National K...
Barclays analyst Sarah James initiates coverage on DaVita (NYSE:DVA) with a Equal-Weight rating and announces Price Target o...
Novo Nordisk's FLOW trial reveals a 24% reduction in kidney disease progression, cardiovascular events, and death with sema...
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Expansion would make DaVita the largest dialysis services provider in Latin America
Fresenius Medical Care Q4 2023 revenue: €4.9 billion. Patient volume growth is expected at 0.5%-2% in 2024.
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday.
